2024
The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated with Adjuvant Radiotherapy
Sherwani Z, Damast S, Fields E, Shah S, Beriwal S, Horne Z, Parks E, Kidd E, Leung E, Khoja L, Taunk N, Chino J, Huang C, Russo A, Dyer M, Albuquerque K, Hathout L. The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated with Adjuvant Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s32. DOI: 10.1016/j.ijrobp.2024.07.044.Peer-Reviewed Original ResearchRecurrence-free survivalExternal beam radiationMismatch repair statusOverall survivalAdjuvant radiotherapyVaginal brachytherapyAssociated with decreased RFSPromoter hypermethylationInferior recurrence-free survivalProportion of locoregional recurrenceTreated with adjuvant radiotherapyDepth of myometrial invasionLympho-vascular space invasionMulti-institutional cohort studyRetrospective multi-institutional cohort studyCervical stromal involvementSite of recurrenceKaplan Meier methodPost-surgical resectionCox proportional hazards modelsMulti-institutional studyDeficient mismatch repairProportional hazards modelImpact OSLocoregional recurrencePrognostic Effect of Mismatch Repair Status in Early-Stage Endometrial Cancer Treated With Adjuvant Radiation: A Multi-institutional Analysis
Hathout L, Sherwani Z, Alegun J, Ohri N, Fields E, Shah S, Beriwal S, Horne Z, Kidd E, Leung E, Song J, Taunk N, Chino J, Huang C, Russo A, Dyer M, Li J, Albuquerque K, Damast S. Prognostic Effect of Mismatch Repair Status in Early-Stage Endometrial Cancer Treated With Adjuvant Radiation: A Multi-institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2024, 119: 1158-1165. PMID: 38253292, DOI: 10.1016/j.ijrobp.2024.01.203.Peer-Reviewed Original ResearchRecurrence-free survivalEndometrioid endometrial adenocarcinomaMismatch repair statusAdjuvant radiation therapyOverall survivalRadiation therapyVaginal brachytherapyMismatch repair deficiencyAssociated with worse recurrence-free survivalMulti-institutional retrospective cohort studyTreated with adjuvant radiation therapyAssociated with recurrence-free survivalMultivariate analysisExternal beam radiation therapyRecurrence-free survival ratesMismatch repair deficiency statusBeam radiation therapyGrades 1 to 2Kaplan-Meier methodOutcomes of patientsMulti-institutional analysisRetrospective cohort studyCox proportional hazards modelsProportional hazards modelAdjuvant radiation
2023
The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma
Patrich T, Wang Y, Elshaikh M, Zhu S, Damast S, Li J, Fields E, Beriwal S, Keller A, Kidd E, Usoz M, Jolly S, Jaworski E, Leung E, Taunk N, Chino J, Russo A, Lea J, Lee L, Albuquerque K, Hathout L. The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma. American Journal Of Clinical Oncology 2023, 46: 114-120. PMID: 36625449, DOI: 10.1097/coc.0000000000000975.Peer-Reviewed Original ResearchConceptsStage IIIC endometrial carcinomaRecurrence-free survivalNon-black patientsParaaortic lymph nodesGrade 3 tumorsBlack patientsOverall survivalEndometrial carcinomaWorse OSLymph nodesNonendometrioid histologyPositive paraaortic lymph nodesRetrospective multi-institutional studyKaplan-Meier methodMulti-institutional studySPSS version 27Adjuvant chemotherapyConcurrent chemoradiotherapyHazard ratioRFS ratesClinical outcomesRandomized trialsNonsignificant trendPatientsPrognostic covariates
2022
Racial Disparities in Patients with Stage IIIC Endometrial Cancer
Patrich T, Wang Y, Elshaikh M, Zhu S, Damast S, Li J, Fields E, Beriwal S, Keller A, Kidd E, Usoz M, Jolly S, Jaworski E, Leung E, Donovan E, Taunk N, Chino J, Russo A, Lea J, Lee L, Albuquerque K, Hathout L. Racial Disparities in Patients with Stage IIIC Endometrial Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e273-e274. DOI: 10.1016/j.ijrobp.2022.07.1283.Peer-Reviewed Original ResearchPositive paraaortic lymph nodesNon-black patientsRecurrence-free survivalExternal beam radiation therapyStage IIIC endometrial carcinomaNon-endometrioid histologyGrade 3 tumorsLymphovascular space invasionOverall survivalBlack patientsVaginal cuff brachytherapyEndometrial carcinomaCervical involvementWorse OSHazard ratioPropensity scoreStage IIIC endometrial cancerMulti-institutional cohort studyRetrospective multi-institutional cohort studyCox proportional hazards modelRacial disparitiesParaaortic lymph nodesKaplan-Meier methodProportional hazards modelBeam radiation therapy
2021
Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalEndometrioid endometrial cancerVaginal brachytherapyPMMR patientsOverall survivalEEC patientsEndometrial cancerExact testThree-year recurrence-free survivalEarly-stage endometrial cancerCox proportional hazards regressionPoor recurrence-free survivalAdjuvant vaginal brachytherapyThree-year OSMultivariable Cox regressionLympho-vascular invasionSignificant prognostic variablesProportional hazards regressionLog-rank testKaplan-Meier estimatesDeficient mismatch repairMismatch repair statusFisher's exact testMismatch repair deficiencyDMMR status
2019
Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy
Hochreiter A, Kelly JR, Young MR, Litkouhi B, Black JD, Stromberger C, Higgins S, Schwartz PE, Damast S. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy. International Journal Of Gynecological Cancer 2019, 30: 48. PMID: 31722964, DOI: 10.1136/ijgc-2019-000675.Peer-Reviewed Original ResearchConceptsDisease-free survivalLower uterine segment involvementPelvic recurrence-free survivalStage IB grade 2Uterine segment involvementLymph node dissectionRecurrence-free survivalEndometrial cancerRisk factorsVaginal brachytherapyOverall survivalGrade 2Endometrioid histologyNode dissectionPelvic recurrenceSegment involvementLymph nodesMyometrial invasionMultivariable Cox proportional hazards regressionEarly-stage endometrial cancerUnderwent lymph node dissectionCox proportional hazards regressionReduced disease-free survivalAdjuvant vaginal brachytherapySole adjuvant therapy
2015
High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma
Damast S, Higgins SA, Ratner E, De Leon MC, Mani S, Silasi DA, Azodi M, Santin A, Rutherford T, Schwartz PE. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. Journal Of Contemporary Brachytherapy 2015, 7: 35-40. PMID: 25829935, PMCID: PMC4371058, DOI: 10.5114/jcb.2015.48539.Peer-Reviewed Original ResearchRecurrence-free survivalUterine serous carcinomaComprehensive surgical stagingOverall survivalSurgical stagingSerous carcinomaPara-aortic lymph node dissectionFIGO 2009 stage ICarboplatin-paclitaxel chemotherapyInstitutional chart reviewIsolated vaginal recurrencesSimultaneous lung metastasisLymph node dissectionPelvic control rateKaplan-Meier methodRate vaginal brachytherapyCases of recurrenceMedian followNode dissectionPeritoneal cytologyVaginal brachytherapyVaginal recurrenceTotal hysterectomyChart reviewBrachytherapy dose